iifl-logo

Glenmark Pharmaceuticals Ltd Share Price

1,515.45
(0.41%)
Apr 2, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,509.2
  • Day's High1,530.05
  • 52 Wk High1,830.95
  • Prev. Close1,509.2
  • Day's Low1,492.55
  • 52 Wk Low 959.05
  • Turnover (lac)5,086.6
  • P/E18.48
  • Face Value1
  • Book Value865.85
  • EPS81.65
  • Mkt. Cap (Cr.)42,764.2
  • Div. Yield0.17
View All Historical Data
Loading...
  • Open1,419.65
  • Day's High1,453.65
  • Spot1,416.4
  • Prev. Close1,428.6
  • Day's Low1,401
  • ViewShort Covering
  • Market Lot725
  • OI(Chg %)-3,93,675 (-39.78%)
  • Roll Over%9.07
  • Roll Cost-0.46
  • Traded Vol.18,87,900 (-23.5%)
View More Futures

Glenmark Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,509.2

Prev. Close

1,509.2

Turnover(Lac.)

5,086.6

Day's High

1,530.05

Day's Low

1,492.55

52 Week's High

1,830.95

52 Week's Low

959.05

Book Value

865.85

Face Value

1

Mkt Cap (₹ Cr.)

42,764.2

P/E

18.48

EPS

81.65

Divi. Yield

0.17

Glenmark Pharmaceuticals Ltd Corporate Action

30 Aug 2024

12:00 AM

AGM

Announcement Date: 30 Aug, 2024

arrow

3 Feb 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

30 Aug 2024

12:00 AM

BookCloser

arrow

24 May 2024

12:00 AM

Dividend

Dividend Amount: 2.5

arrow

Glenmark Pharmaceuticals Ltd NEWS AND UPDATE

Glenmark Gets USFDA Nod for Olopatadine Ophthalmic Solution
23 Mar 2025|11:40 AM

This approval would allow Glenmark Therapeutics Inc., USA to market the product in the US market and would further fortify its ophthalmic portfolio.

Read More
Glenmark Expands US Portfolio with Acetylcysteine Injection Launch
3 Mar 2025|09:57 PM

Acetylcysteine Injection will be launched in 6 gm/30 mL (200 mg/mL) single-dose vials, and will be made available to hospitals and other system-wide healthcare providers.

Read More
Glenmark Pharma Settles US Legal Dispute Over Generic Zetia
24 Feb 2025|04:15 PM

The lawsuits included one on a generic version of Zetia, a cholesterol drug, as well as four other lawsuits involving Vytorin, a combination drug that contains Zetia.

Read More
Glenmark Pharma Q3 Revenue Jumps 35% to ₹3,388 Crore
16 Feb 2025|10:34 PM

EBITDA surged to ₹600.3 crore, up from a loss of ₹208.7 crore in the year-ago quarter, indicating better operational efficiency

Read More
Glenmark Hit with ₹121.25 Crore Tax Demand, Company to Appeal
10 Feb 2025|09:25 AM

It also appropriates ₹5.86 crore that Glenmark had already paid for surrendering IGST refunds relating to non-realisation of export proceeds.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Glenmark Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

03 Apr, 2025|07:57 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 46.64%

Foreign: 0.00%

Indian: 46.64%

Non-Promoter- 37.39%

Institutions: 37.39%

Non-Institutions: 15.95%

Custodian: 0.00%

Share Price

Glenmark Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

28.22

28.22

28.22

28.22

Preference Capital

0

0

0

0

Reserves

22,942.4

17,849.25

16,710.37

14,781.29

Net Worth

22,970.62

17,877.47

16,738.59

14,809.51

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

7,567.93

6,712.63

6,403.23

7,989.23

yoy growth (%)

12.74

4.83

-19.85

30.64

Raw materials

-2,999.45

-2,665.99

-2,378.59

-2,425.49

As % of sales

39.63

39.71

37.14

30.35

Employee costs

-1,107.39

-1,072.32

-1,021.92

-914.47

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

1,869.86

1,516.09

1,218.82

2,789.34

Depreciation

-150.81

-138.53

-118.2

-104.93

Tax paid

-294.31

-180.09

-204.47

-412.28

Working capital

463.74

-1,507.52

-180.36

1,492.86

Other operating items

View Cash Flow
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

12.74

4.83

-19.85

30.64

Op profit growth

44.93

-3.21

-53.51

64.2

EBIT growth

20.49

25.73

-52.08

65.02

Net profit growth

21.77

33.53

-52.61

44.21

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

11,635.46

11,431.94

12,174.2

10,806.03

10,397.23

Excise Duty

0

0

0

0

0

Net Sales

11,635.46

11,431.94

12,174.2

10,806.03

10,397.23

Other Operating Income

177.64

151.3

130.71

137.9

243.74

Other Income

1,237.32

755.86

166.67

94.76

192.48

Glenmark Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,713.65

130.564,11,3061,181.050.795,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,666

72.521,50,342.825940.532,297513.62

Cipla Ltd

CIPLA

1,452.35

25.211,17,322.541,438.150.894,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,207.1

59.541,08,614.114850.872,330222.38

Mankind Pharma Ltd

MANKIND

2,421.9

51.6699,891.45416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Glenmark Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

Glenn Saldanha

Executive Director (Corporate)

Cheryl Pinto

Executive Director & Group CFO

V S Mani

Non Executive Director

B E Saldanha

Independent Non Exe. Director

Rajesh Desai.

Independent Non Exe. Director

Sona Saira Ramasastry

Independent Non Exe. Director

Dipankar Bhattacharjee

Independent Non Exe. Director

V R Iyer

Additional Director

Pradeep Kumar Sinha

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology. Its branded generics business has a significant presence in markets across emerging economies including India. The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland. The generics business services the requirements of developed markets like the US and Western Europe. The API business sells products in over 80 countries including the US, various countries in the EU, South America and India.In the year 1979, the company entered dermatology market with the launch of Candid Cream. In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In the year 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril.In the year 1989, the company started operations in Afghanistan, Sri Lanka, Kenya and Mauritius. In the year 1982, the company expanded th
Read More

Company FAQs

What is the Glenmark Pharmaceuticals Ltd share price today?

The Glenmark Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1515.45 today.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd is ₹42764.20 Cr. as of 02 Apr ‘25

What is the PE and PB ratio of Glenmark Pharmaceuticals Ltd?

The PE and PB ratios of Glenmark Pharmaceuticals Ltd is 18.48 and 1.78 as of 02 Apr ‘25

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

The 52-week high/low is the highest and lowest price at which a Glenmark Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Pharmaceuticals Ltd is ₹959.05 and ₹1830.95 as of 02 Apr ‘25

What is the CAGR of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd's CAGR for 5 Years at 48.05%, 3 Years at 48.77%, 1 Year at 53.54%, 6 Month at -7.84%, 3 Month at -7.56% and 1 Month at 15.40%.

What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?

The shareholding pattern of Glenmark Pharmaceuticals Ltd is as follows:
Promoters - 46.65 %
Institutions - 37.39 %
Public - 15.96 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.